Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][3] - The company will present and host one-on-one investor meetings at the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 [1][2] Company Overview - Reviva's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [3] - The company has been granted composition of matter patents for both drug candidates in the United States, Europe, and several other countries [3]